Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
GERMAN healthcare group Fresenius on Wednesday toned up its earnings guidance for the year as demand for recently launched generic infusion drugs continued to grow at higher-than-expected rates.
For 2017, it now expects adjusted net income to grow by 19 to 21 per cent,...